Evidence map›Paper›PMID 32761250›Full record

ArticlePharmaceutical research2020

Enhanced Cellular Uptake and Gene Silencing Activity of Survivin-siRNA via Ultrasound-Mediated Nanobubbles in Lung Cancer Cells.

Hasan Akbaba, Gülşah Erel-Akbaba, Mustafa Kotmakçı, Yücel Başpınar

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hasan AkbabaDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, İzmir, Turkey. hasan.akbaba@ege.edu.tr.ORCID http://orcid.org/0000-0001-9273-6346
Gülşah Erel-AkbabaDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, İzmir, Turkey.
Mustafa KotmakçıDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, İzmir, Turkey.
Yücel BaşpınarDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, İzmir, Turkey.
Ege University · TRIzmir Kâtip Çelebi University · TR

Funding

Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 116S213
6 · The paper itself

Abstract

purposePaclitaxel is a first-line drug for the therapy of lung cancer, however, drug resistance is a serious limiting factor, related to overexpression of anti-apoptotic proteins like survivin. To overcome this phenomenon, developing novel ultrasound responsive nanobubbles - nanosized drug delivery system- for the delivery of paclitaxel and siRNA in order to silence survivin expression in the presence of ultrasound was aimed.

methodsPaclitaxel-carrying nanobubble formulation was obtained by modifying the multistep method. Then, the complex formation of the nanobubbles - paclitaxel formulation with survivin-siRNA, was examined in terms of particle size, polydispersity index, zeta potential, and morphology. Furthermore, siRNA binding and protecting ability, cytotoxicity, cellular uptake, gene silencing, and induction of apoptosis studies were investigated in terms of lung cancer cells.

resultsDeveloped nanobubbles have particle sizes of 218.9-369.6 nm, zeta potentials of 27-34 mV, were able to protect siRNA from degradation and delivered siRNA into the lung cancer cells. Survivin expression was significantly lower compared with the control groups and enhanced apoptosis was induced by the co-delivery of survivin-siRNA and paclitaxel. Furthermore, significantly higher effects were obtained in the presence of ultrasound induction.

conclusionThe ultrasound responsive nanobubble system carrying paclitaxel and survivin-siRNA is a promising and effective approach against lung cancer cells.

Indexed as

A549 CellsAntineoplastic AgentsApoptosisCell Line, TumorCell SurvivalDrug CarriersDrug Delivery SystemsGene SilencingHumansNanoparticlesPaclitaxelRNA, Small InterferingSurvivinUltrasonic WavesAntineoplastic AgentsDrug CarriersPaclitaxelRNA, Small InterferingSurvivinlung cancer cellnanobubblepaclitaxelsurvivin-siRNAultrasound

Identifiers

PMID32761250
OpenAlexW3047409920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.